Development of a pilot-scale bacterial fermentation for plasmid-based biopharmaceutical production using a stoichiometric medium

Biotechnology and Bioprocess Engineering

Volumn 13, Issue 2, 2008, Pages 158-167

  Danquah, Michael K ^a   Forde, Gareth M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Biopharmaceutical; DNA vaccines; Gene therapy; Pilot scale fermentation; Plasmid DNA

Indexed keywords

DNA VACCINE; GLYCEROL; PLASMID DNA;

ARTICLE; BACTERIAL KINETICS; BATCH FERMENTATION; CONTROLLED STUDY; DRUG STABILITY; ESCHERICHIA COLI; FED BATCH FERMENTATION; FERMENTATION MEDIUM; MATHEMATICAL COMPUTING; NONHUMAN; PILOT STUDY; STOICHIOMETRY; TEMPERATURE DEPENDENCE; VOLUMETRY;

BACTERIA (MICROORGANISMS);

EID: 43749107940     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12257-007-0080-2     Document Type: Article

References (26)

1. Institute of Medicine (2004) Forum on Microbial Threats, Board on Global Health. The Threat of Pandemic Influenza: Are We Ready? US National Academy of Sciences, Washington, DC, USA.
2. Wahlberg, D. and C. Seabrook (2004) Flu vaccine production system shaky. New York Times Syndicate. October 10.
3. Robinson, H. L., L. A. Hunt, and R. G. Webster (1993) Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11: 957-960.
4. Hahn, U. K. R. Boehm, and W. Beyer (2006) DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24: 4569-4571.
5. Galloway, D. R. and L. Baillie (2004) DNA vaccines against anthrax. Expert Opin. Biol. Ther. 4: 1661-1667.
6. Ferrari, M. E., G. Hermanson, and A. Rolland (2004) Development of anthrax DNA vaccines. Curr. Opin. Mol. Ther. 6: 506-512.
7. Doolan, D. L. and S. L. Hoffman (2002) Nucleic acid vaccines against malaria. Chem. Immunol. 80: 308-321.
8. Ivory, C. and K. Chadee (2004) DNA vaccines: designing strategies against parasitic infections. Genet. Vaccines Ther. 2: 17.
9. Gurunathan, S., D. M. Klinman, and R. A. Seder (2000) DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18: 927-974.
10. Liu, M. A. and J. B. Ulmer (2005) Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55: 25-40.
11. Sedegah, M., W. O. Rogers, A. Belmonte, M. Belmonte, G. Banania, N. Patterson, M. Ferrari, D. C. Kaslow, D. J. Carucci, T. L. Richie, and D. L. Doolan (2006) Vaxfectin™ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 24: 1921-1927.
12. MacGregor, R. R., R. Ginsberg, K. E. Ugen, Y. Baine, C. U. Kang, X. M. Tu, T. Higgins, D. B. Weiner, and J. D. Boyer (2002) T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS 16: 2137-2143.
13. United States Food and Drug Administration (1996) Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications, US Food and Drug Administration, Rockville, MD, USA.
14. Kelly, W. J. (2003) Perspectives on plasmid-based gene therapy: challenges for the product and the process. Biotechnol. Appl. Biochem. 37: 219-223.
15. Stanier, R. Y., M. Doudoroff, and E. A. Adelberg (1976) The Microbial World. 3rd ed., Prentice-Hall, Englewood Cliffs, NJ, USA.
16. Danquah, M. K. and G. M. Forde (2007) Growth medium selection and its economic impact on plasmid DNA production. J. Biosci. Bioeng. 104: 490-497.
17. Diogo, M. M., S. C. Ribeiro, J. A. Queiroz, G. A. Monteiro, N. Tordo, P. Perrin, and D. M. F. Prazeres (2001) Production, purification and analysis of an experimental DNA vaccine against rabies. J. Gene Med. 3: 577-584.
18. Wong, E. M., M. A. Muesing, and B. Polisky (1982) Temperature-sensitive copy number mutants of ColE1 are located in an untranslated region of the plasmid genome. Proc. Natl. Acad. Sci. USA 79: 3570-3574.
19. Carnes, A. E. (2005) Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess International 3: 36-44.
20. Prather, K. J., S. Sagar, J. Murphy, and M. Chartrain (2003) Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme and Microb. Technol. 33: 865-883.
21. Schmidt, T., K. Friehs, E. Flaschel, and M. Schleef (2003) Method for the isolation of CCC plasmid DNA. US Patent 6,664,078.
22. Durland, R. H. and E. M. Eastman (1998) Manufacturing and quality control of plasmid-based gene expression systems. Adv. Drug Deliv. Rev. 30: 33-48.
23. Lahijani, R., G. Hulley, G. Soriano, N. A. Horn, and M. Marquet (1996) High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum. Gene Ther. 7: 1971-1980.
24. Wang, Z., G. Le, Y. Shi, and G. Wegrzyn (2001) Medium design for plasmid DNA production based on stoichiometric model. Process Biochem. 36: 1085-1093.
25. O'Kennedy, R. D., J. M. Ward, and E. Keshavarz-Moore (2003) Effects of fermentation strategy on the characteristics of plasmid DNA production. Biotechnol. Appl. Biochem. 37: 83-90.
26. Carnes, A. E., C. P. Hodgson, and J. A. Williams (2006) Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol. Appl. Biochem. 45: 155-166.